Product Description
A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lirilumab?redirect=true)
Mechanisms of Action: KIR2DL1 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, France, Italy, Netherlands, Spain, United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Head and Neck Cancer|Oncology Solid Tumor Unspecified|Oncology Unspecified|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02813135 |
ESMART | P2 |
Recruiting |
Oncology Unspecified |
2031-02-01 |
2026-01-17 |
||
2016-001359-36 |
2016-001359-36 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2023-05-21 |
2025-05-06 |
Treatments |
|
NCT03341936 |
NCT03341936 | P2 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2021-07-06 |
12% |
2022-06-17 |
Patient Enrollment|Primary Endpoints|Treatments |